Drug Trial Radar · NCT04908553
Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
Jul 1, 2021
Primary completion
Mar 30, 2025
Study completion May 31, 2025
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Research objective: To explore the safety and dose exploration of Remimazolam Tosilate for Injection for induction and maintenance of general anesthesia in elective short-term surgery in adults. Main research indicators:(1)Success rate of sedation during induction and maintenance of general anesthesia with remazolam tosylate;(2)The incidence and severity of hypotension in the induction and maintenance phases Study design: Multi-center, randomized, double-blind clinical study. Subject population: patients undergoing elective short-term surgery. Research data collection period: The subject signs the consent form until discharge or death in the hospital or withdrawal from the research. Number of research centers/sample size: It is planned to enroll 600 patients from 11 hospitals. Research process: The researchers will include patients who meet the enrollment criteria and agree to participate in the investigation of the support laryngoscope surgery and minor head and neck surgery patients from the elective surgery patients.
Conditions
- Hypotension During Surgery
Interventions
Remimazolam Tosilate for Injection 0.1mg/kgDrug
Remimazolam Tosilate for Injection 0.1mg/kg at induction
Remimazolam Tosilate for Injection 0.15mg/kgDrug
Remimazolam Tosilate for Injection 0.15mg/kg at induction
Remimazolam Tosilate for Injection 0.2mg/kgDrug
Remimazolam Tosilate for Injection 0.2mg/kg at induction
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of hypotension during the anesthesiaTime frame: during the anesthesia procedure
- The rate of Successful sedation during the anesthesiaTime frame: during the anesthesia procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TongjiHospital
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.